PTEN mRNA@HA-LNP (f0345b)

**PTEN mRNA@HA-LNP** is an experimental, topically administered mRNA nanomedicine developed in an academic preclinical study for localized melanoma immunotherapy. It encapsulates chemically modified messenger RNA encoding the tumor-suppressor phosphatase and tensin homolog protein in a hyaluronate-conjugated lipid nanoparticle containing hyaluronic acid-dimyristoyl glycerol. The hyaluronate surface component replaces PEG-like stabilization functionality, promotes skin and tumor penetration, and supports CD44-mediated uptake by CD44-expressing tumor cells. Following intracellular delivery, the mRNA transiently restores PTEN protein expression, suppressing PI3K-AKT signaling, reducing melanoma-cell viability, inducing immunogenic cell death, and enhancing antitumor immune activation in melanoma models. The reported evidence is preclinical, including in vitro experiments and topical treatment of melanoma-bearing mice. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0168365925011320))

Other names

PTEN mRNA@hyaluronic acid-lipid nanoparticlePTEN mRNA@hyaluronated lipid nanoparticlePTEN mRNA-loaded HA-LNP